NasdaqGS - Nasdaq Real Time Price USD

MeiraGTx Holdings plc (MGTX)

5.71

+0.23

+(4.20%)

As of 10:14:59 AM EDT. Market Open.

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters

GlobeNewswire 23 days ago

MGTX
+4.20%
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

MeiraGTx (MGTX) delivered earnings and revenue surprises of -34.21% and 76.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 24 days ago

MGTX
+4.20%
MeiraGTx Reports First Quarter 2025 Financial and Operational Results

- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease - U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson’s disease - Gained alignment wit

GlobeNewswire 24 days ago

MGTX
+4.20%
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinic

GlobeNewswire 28 days ago

MGTX
+4.20%
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

BEAM

MGTX
+4.20%
US High Growth Tech Stocks to Watch in 2023

As the U.S. market experiences heightened volatility with major indices like the S&P 500 and Nasdaq Composite closing sharply lower amid tariff concerns, investors are closely monitoring economic indicators that could impact small-cap companies and technology stocks. In such a climate, identifying high-growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting trade policies, making them noteworthy in this unpredictable...

Simply Wall St. last month

MGTX
+4.20%

AKBA

ATYR
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 2 months ago

GLPG

GLPGF

PTCT
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 2 months ago

ANAB

MGTX
+4.20%
MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future

MeiraGTx Holdings plc ( NASDAQ:MGTX ) is possibly approaching a major achievement in its business, so we would like to...

Simply Wall St. 2 months ago

MGTX
+4.20%
MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment

We recently published a list of Top 10 AI News Updates Taking Wall Street By Storm. In this article, we are going to take a look at where MeiraGTx Holdings plc (NASDAQ:MGTX) stands against other top AI news updates taking Wall Street by storm. Escalating costs for developing bigger and more powerful artificial models has […]

Insider Monkey 2 months ago

MGTX
+4.20%
MeiraGTx and Hologen launch AI-backed gene therapy venture

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from Hologen.

Pharmaceutical Technology 2 months ago

MGTX
+4.20%
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

BioPharma Dive 2 months ago

MGTX
+4.20%
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease - MeiraGTx and Hologen have created the first neuro-AI clinical drug development company to transform the discovery and development of therapies targeting CNS circuitry in neurodegen

GlobeNewswire 2 months ago

MGTX
+4.20%
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products - MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally delivered CNS genetic

GlobeNewswire 2 months ago

MGTX
+4.20%
High Growth Tech Stocks In The United States Spotlighting Three Leaders

Over the last 7 days, the United States market has dropped 3.0%, yet it remains up by 18% over the past year with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these promising growth trends.

Simply Wall St. 3 months ago

AUPH

CINT

MGTX
+4.20%
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind.

Pharmaceutical Technology 3 months ago

MGTX
+4.20%
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved visual acuity, functional vision, and protection against progressive retinal degenerationFollowing the strong safety and substantial efficacy demonstrated in this first cohort of 4 children treated unilaterally, a further 7 children have now been treated bilaterally and all showed substantial benef

GlobeNewswire 3 months ago

MGTX
+4.20%
MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions

Key Insights Significant control over MeiraGTx Holdings by private equity firms implies that the general public has...

Simply Wall St. 4 months ago

MGTX
+4.20%
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary technology platformsLONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the U.S. Food and Drug Administration (FDA) has granted the Company Rare Pediatric Disease Designation to i

GlobeNewswire 4 months ago

MGTX
+4.20%
Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where MeiraGTx Holdings plc (NASDAQ:MGTX) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology […]

Insider Monkey 4 months ago

MGTX
+4.20%

Performance Overview

Return	MGTX	S&P 500 (^GSPC)
YTD	-6.24%	+2.15%
1-Year	+17.25%	+12.23%
3-Year	-28.80%	+45.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MeiraGTx Holdings plc (MGTX)

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

US High Growth Tech Stocks to Watch in 2023

Biotech stocks slide as Marks resignation seen being negative for sector

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future

MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment

MeiraGTx and Hologen launch AI-backed gene therapy venture

MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

High Growth Tech Stocks In The United States Spotlighting Three Leaders

MeiraGTx seeks UK approval after gene therapy restores sight in children born blind

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Performance Overview